TriSalus Life Sciences (TLSI) Return on Capital Employed (2021 - 2026)

TriSalus Life Sciences' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 67.75% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 15103.0% year-over-year to 67.75% in Q1 2026; TTM through Mar 2026 was 67.75%, a 15103.0% increase from a year earlier, with the FY2025 full-year figure at 148.45%, up 10884.0% from the prior year.
• Return on Capital Employed rose to 67.75% in Q1 2026 per TLSI's latest filing, from 110.44% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 1.17% in Q2 2022 and bottomed at 817.14% in Q1 2024.
• The 5-year median for Return on Capital Employed is 182.56% (2023), against an average of 215.54%.
• Across the five-year window, Return on Capital Employed sank 63458 bps in 2024 and soared 59836 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 19.98% in 2022, then slumped by 1793 bps to 378.2% in 2023, then surged by 38 bps to 233.38% in 2024, then surged by 53 bps to 110.44% in 2025, then soared by 39 bps to 67.75% in 2026.
• Per Business Quant, the three latest TLSI Return on Capital Employed figures stand at 67.75% (Q1 2026), 110.44% (Q4 2025), and 111.7% (Q3 2025).